Individualising HIV treatment--pharmacogenetics and immunogenetics.
Telenti
Amalio
A
Division of Infectious Diseases, University Hospital, CHUV 1011 Lausanne, Switzerland. Amallo.Telenti@chuv.hospvd.ch
Aubert
Vincent
V
Spertini
François
F
D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015224:Dideoxynucleosides / Q000009:adverse effects* / Q000627:therapeutic use; D004342:Drug Hypersensitivity / Q000235:genetics* / Q000276:immunology; D005820:Genetic Testing; D015658:HIV Infections / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D006239:Haplotypes; D006801:Humans; D008285:Major Histocompatibility Complex / Q000235:genetics; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D000099227:Abacavir
D019380:Anti-HIV Agents; D015224:Dideoxynucleosides; D018894:Reverse Transcriptase Inhibitors; D000099227:Abacavir